A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1 (NCT01745965)
Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+).
A new high potential trastuzumab conjugate ado-trastuzumab emtansine (T-DM1) (Kadcyla®; Genentech, Inc.) (trastuzumab was linked with the cytotoxic agent mertansine DM1) was tested with endocrine therapy and without against a standard arm with trastuzumab and endocrine therapy.
- Condition: Breast Cancer
- Phase: II
- Estimated Enrollment: 380
- Start: November 2012
- Estimated Completion: October 2020
- Last verified: June 2015
Last Editorial review: July 27, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.